New frontiers in regenerative medicine in cardiology: The potential of Wharton's jelly mesenchymal stem cells

Current Stem Cell Research and Therapy

Volumn 8, Issue 1, 2013, Pages 39-45

  Corrao, Simona ^a   La Rocca, Giampiero ^a,b   Lo Iacono, Melania ^a   Zummo, Giovanni ^b   Gerbino, Aldo ^b   Farina, Felicia ^b   Anzalone, Rita ^b  

^a Istituto Euro Mediterraneo di Scienza e Tecnologia IEMEST   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Heart failure; Immune modulation; Mesenchymal stem cells; Regenerative medicine; Tissue repair; Wharton's jelly

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CHEMOKINE RECEPTOR CXCR4; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 8; SCATTER FACTOR; SOMATOMEDIN C; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR TBX5; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADIPOSE DERIVED STEM CELL; CARDIOLOGY; CARDIOMYOPATHY; CELL DIFFERENTIATION; CORD BLOOD STEM CELL TRANSPLANTATION; EMBRYONIC STEM CELL; HEART MUSCLE; HEART REGENERATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; TISSUE REGENERATION; TISSUE REPAIR;

CARDIOLOGY; CARDIOVASCULAR DISEASES; HUMANS; MESENCHYMAL STROMAL CELLS; REGENERATIVE MEDICINE; WHARTON JELLY;

EID: 84879778296     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X11308010006     Document Type: Review

References (110)

1. Anversa P, Leri A, Kajstura J. Cardiac regeneration. J Am Coll Cardiol 2006; 47 (9): 1769-76.
2. Bearzi C, Rota M, Hosoda T, et al. Human cardiac stem cells. Proc Natl Acad Sci 2007; 104 (35): 14068-73.
3. van Weerd JH, Koshiba-Takeuchi K, Kwon C, Takeuchi JK. Epigenetic factors and cardiac development. Cardiovasc Res 2011; 91 (2): 203-11.
4. Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ. Paracrine mechanisms of stem cell separative and regenerative actions in the heart. J Mol Cell Cardiol 2011; 50 (2): 280-9.
5. Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 2001; 344 (23): 1750-7.
6. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114 (6): 763-76.
7. Leontiadis E, Manginas A, Cokkinos DV. Cardiac repair-fact or fancy? Heart Fail Rev 2006; 11 (2): 155-70.
8. Barile L, Messina E, Giacomello A, Marbàn E. Endogenous cardiac stem cells. Prog Cardiovasc Dis 2007; 50 (1): 31-48.
9. Guan K, Hasenfuss G. Do stem cells in the heart truly differentiate into cardiomyocytes? J Mol Cell Cardiol 2007; 43 (4): 377-87.
10. Schuldt AJT, Rosen MR, Gaudette GR, Cohen IS. Repairing damaged myocardium: evaluating cells used for cardiac regeneration. Curr Treat Opt Cardiovasc Med 2008; 10(1): 59-72.
11. Khattar P, Friedrich FW, Bonne G, et al. Distinction between two population of islet-1-positive cells in hearts of different murine strains. Stem Cells Dev 2011; 20 (6): 1043-52.
12. Vandervelde S, van Luyn MJA, Tio RA, Harmsen MC. Signaling factors in stem cell-mediated repair of infarcted myocardium. J Mol Cell Cardiol 2005; 39 (2): 363-76.
13. Hwang H, Kloner RA. Improving regenerating potential of the heart after myocardial infarction: factor-based approach. Life Sci 2010; 86 (13-14): 461-72.
14. Wiehe JM, Kaya Z, Homann JM, et al. GMP-adapted overexpression of CXCR4 in human mesenchymal stem cells for cardiac reapir. Int J Cardiol 2012; [Epub ahead of print].
15. Takeda K, Lin J, Okubo S, et al. Transient glugose deprivation causes upregulation of heme oxygenase-1 and cyclooxygenase-2 expression in cardiac fibroblasts. J Mol Cell Cardiol 2004; 36 (6): 821-30.
16. La Rocca G, Di Stefano A, Eleuteri E, et al. Oxidative stress induces myeloperoxidase expression in endocardial endothelial cells from patients with chronic heart failure. Basic Res Cardiol 2009; 104 (3): 307-20.
17. Anzalone R, La Rocca G, Di Stefano A, et al. Role of endothelial cell stress in the pathogenesis of chronic heart failure. Front Biosci 2009; 14: 2238-47.
18. Eleuteri E, Di Stefano A, Ricciardolo FL, et al. Increased nitrotyrosine plasma levels in relation to systemic markers of inflammation and myeloperoxidase in chronic heart failure. Int J Cardiol 2009; 135 (3): 386-90.
19. Lau S, Patnaik N, Sayen MR, Mestril R. Simultaneous overexpression of two stress proteins in rat cardiomyocytes and myogenic cells confers protection against ischemia-induced injury. Circulation 1997; 96 (7): 2287-94.
20. Lin KM, Lin B, Lian IY, Mestril R, Scheffler IE and Dillmann WH. Combined and individual mitochondrial HSP60 and HSP10 expression in cardiac myocytes protects mitochondrial function and prevents apoptotic cell deaths induced by simulated ischemiareoxygenation. Circulation 2001; 103 (13): 1787-92.
21. Gupta S, Knowlton AA. Cytosolic heat shock protein 60, hypoxia, and apoptosis. Circulation 2002; 106 (21): 2727-33.
22. Kirchhoff SR, Gupta S, Knowlton AA. Cytosolic heat shock protein 60, apoptosis, and myocardial injury. Circulation 2002; 105 (24): 2899-904.
23. Shan YX, Liu TJ, Su HF, Samsamshariat A, Mestril R, Wang PH. Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. J Mol Cell Cardiol 2003; 35 (9): 1135-43.
24. Maurel A, Azarnoush K, Sabbah L et al. Can cold or heat shock improve skeletal myoblast engraftment in infracted myocardium? Transplantation 2005; 80 (5): 660-5.
25. Gupta S, Knowlton AA. HSP60 trafficking in adult cardiac myocytes: role of the exosomal pathway. Am J Physiol Heart Circ Physiol 2007; 292 (6): H3052-6.
26. Wang X, Zhao T, Huang W, et al. Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells Dec 2009; 27 (12): 3021-31.
27. Wang Y, Chen L, Hagiwara N, Knowlton AA. Regulation of heat shock protein 60 and 72 expression in failing heart. J Mol Cell Cardiol 2010; 48 (2): 360-6.
28. Eleuteri E, Magno F, Gnemmi I, et al. Role of oxidative and nitrosative stress biomarkers in chronic heart failure. Front Biosci 2009; 14: 2230-7.
29. Stubbs SL, Crook JM, Morrison WA, Newcomb AE. Toward clinical application of stem cells for cardiac regeneration. Heart Lung Circ 2011; 20 (3): 173-9.
30. Vunjak-Novakovic G, Lui KO, Tandon N, Chien KR. Bioengineering heart muscle: a paradigm for regenerative medicine. Annu Rev Biomed Eng 2011; 13: 245-67.
31. Anzalone R, Corrao S, Lo Iacono M, et al. Isolation and characterization of CD276+/HLA-E+ human sub-endocardial mesenchymal stem cells from chronic heart failure patients: analysis of differentiative potential and immunomodulatory markers expression. Stem Cell Dev 2013; 22(1): 1-17.
32. Martin CM. Review of stem cell-based therapy for the treatment of cardiovascular disease. J Cardiovasc Trans Res 2008; 1 (2): 106-14.
33. Yang S, Lin G, Deng L, Lu G-X. Tumourigenic characteristics of embryonal carcinoma cells as a model studying tumour progression of human embryonic stem cells. Cell Prolif 2012; 45 (4): 299-310.
34. Swijnenburg R-J, Tanaka M, Vogel H, et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005; 112 (9 Suppl): I166-72.
35. Abdelwahid E, Siminiak T, Guarita-Souza LC, et al. Stem cell therapy in heart diseases: a review of selected new perspectives, pratical consideration and clinical applications. Curr Cardiol Res 2011; 7 (3): 201-12.
36. Takahashi K, Yamanaka S. Induction of pluripotent stem cell from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126 (4): 663-76.
37. Yoshida Y, Yamanaka S. iPS cells: a source of cardiac regeneration. J Mol Cell Cardiol 2011; 50 (2): 327-32.
38. Xie X, Sun A, Huang Z, et al. Another possible source for cardiac regenerative medicine: reprogramming adult fibroblasts to cardiomyocytes and endothelial progenitor cells. Med Hypotheses 2011; 76 (3): 365-7.
39. Kouris NA, Schaefer JA, Hatta M, et al. Direct fusion of mesenchymal stem cells with cardiomyocytes via VSV-G facilitates stem cell programming. Stem Cell Int 2012; 2012: 414038.
40. Zuba-Surma EK, Abdel-Latif A, Case J, et al. Sca-1 expression is associated with decreased cardiomyogenic differentiation potential of skeletal muscle-derived adult primitive cells. J Mol Cell Cardiol 2006; 41 (4): 650-60.
41. Streckfuss-Bömeke K, Wolf F, Azizian A, et al. Comparative study of human-induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts. Eur Heart J 2012; [Epub ahead of print].
42. Egashira T, Yuasa S, Fukuda K. Induced pluripotent stem cells in cardiovascular medicine. Stem Cell Int 2011;2011: 348960.
43. Mayorga M, Finan A, Penn M. Pre-implantation specification of stem cell to cardiac lineage for regeneration of cardiac tissue. Stem Cell Rev Rep 2009; 5 (1): 51-60.
44. Schoenhard JA, Hatzopoulos AK. Stem cell therapy: pieces of the puzzle. J Cardiovasc Trans Res 2010; 3 (1): 49-60.
45. Tuan RS, Boland G, Tuli R. Adult mesenchymal stem cells and cell-based tissue engineering. Arthritis Res Ther 2003; 5 (1): 32-45.
46. Arnhold S, Klein H, Klinz F-J, Absenger Y, et al. Human bone marrow stroma cells display certain neural characteristics and integrate in the subventricular compartment after injection into the liquor system. Eur J Cell Biol 2006; 85 (6): 551-65.
47. Kim J-M, Lee S-T, Chua K, et al. Systemic transplantation of human adipose stem cells attenuated cerebral inflammation and degeneration in a hemorrhagic stroke model. Brain Res 2007; 1183: 43-50.
48. Elnakish MT, Hassan F, Dakhlallah D, Marsh CB, Alhaider IA, Khan M. Mesenchymal stem cells for cardiac regeneration: translation to bedside reality. Stem Cell Int 2012; 2012: 646038.
49. Chen S-L, Fang W-W, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Am J Cardiol 2004; 94 (1): 92-5.
50. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrowderived cells for cardiac repair: a systematic review and metaanalysis. Arch Intern Med 2007; 167 (10): 989-97.
51. Bai X, Alt E. Myocardial regeneration potential of adipose tissuederived stem cells. Biochem Biophys Res Comm 2010; 401 (3): 321-6.
52. Choundry FA, Mathur A. Stem cell therapy in cardiology. Regen Med 2011; 6 (6 suppl): 17-23.
53. Choi SH, Jung SY, Kwon S-M, Baek SH. Perspective on stem cell therapy for cardiac regeberation-advences and challenges. Circ J 2012; 76 (6): 1307-12.
54. Li XH, Lin QX, Deng CY, Shan ZX, Yang M, Lin SG. Bone marrow mesenchymal stem cells differentiate into functional cardiac phenotypes by cardiac microenvironment. J Mol Cell Cardiol 2007; 42 (2): 295-303.
55. Lin X, Peng P, Cheng L, et al. A natural compound induced cardiogenic differentiation of endogenous MSCs for repair of infracted heart. Differentiation 2012; 83 (1): 1-9.
56. Chang W, Lim S, Song B-W, et al. Phorbol myristate acetate differentiates human adipose-derived mesenchymal stem cells into functional cardiogenic cells. Biochem Biophysic Res Comm 2012; 424(4): 740-6.
57. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13 (12): 4279-95.
58. Cai B, Zhu S, Li J, Chen N, Liu Y, Lu Y. Bone marrow-derived mesenchymal stem cells protected rat cardiomyocytes from premature senescense. Int J Cardiol 2012; 154 (2): 180-2.
59. Sadat S, Gehmert S, Song Y-H, et al. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophysic Res Comm 2007; 363 (3): 674-9.
60. Pourrajab F, Forouzannia SK, Tabatabaee SA. Molecular characteristics of bone marrow mesenchymal stem cells: an appealing source for regenerative medicine. Heart Lung Circ 2012; [Epub ahead of print].
61. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage Potential of Adult Human Mesenchymal Stem Cells Science 1999; 284 (5411): 143-7.
62. Pucci-Minafra I, Minafra S, La Rocca G, et al. Zymographic analysis of circulating and tissue forms of colon carcinoma gelatinase A (MMP-2) and B (MMP-9) separated by mono-and twodimensional electrophoresis. Matrix Biol 2001; 20: 419-27.
63. La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004; 90 (7): 1414-21.
64. La Rocca G, Anzalone R, Magno F, Farina F, Cappello F, Zummo G. Cigarette smoke exposure inhibits extracellular MMP-2 (gelatinase A) activity in human lung fibroblasts. Resp Res 2007; 8: 23.
65. La Rocca G, Corrao S, Lo Iacono M, Corsello T, Farina F, Anzalone R. Novel immunomodulatory markers expressed by WJMSC: an updated review in regenerative and reparative medicine. Open Tissue Eng Regen Med J 2012; 5: 50-8.
66. Bayomy AF, Bauer M, Qju Y, Liao R. Regeneration in heart disease-is ECM the key?. Life Sci 2012; 91 (17-18): 823-7.
67. Liao R, Pfister O, Jain M, Mouquet F. The bone marrow-cardiac axis of myocardial differentiation. The bone marrow-cardiac axis of myocardial regeneration. Progr Cardiovasc Dis 2007; 50 (1): 18-30.
68. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features and potential for homing. Stem Cell 2007; 25 (11): 2739-49.
69. Pappa KI, Anagnou NP. Novel sources of fetal stem cells: where do they fit on the developmental continuum? Regen Med 2009; 4 (3): 423-33.
70. Díaz-Prado S, Muiños-López E, Hermida-Gómez T, et al. Human amniotic membrane as an alternative source of stem cells for regenerative medicine. Differentiation 2011; 81 (3): 162-71.
71. Walther G, Gekas J, Bertrand OF. Amniotic stem cells for cellular cardiomyoplasty. Catheter Cardiovasc Interv 2009; 73 (7): 917-24.
72. Fang C-H, Jin J, Joe J-H, et al. In vivo differentiation of human epithelial cells into cardiomyocyte-like cells and cell transplantation effect on myocardial infarction in rats: comparison with cord blood and adipose tissue-derived mesenchymal stem cells. Cell Transplant 2012; 21(8): 1687-96.
73. Park TS, Gavina M, Chen C-W, et al. Placental perivascular cells for human muscle regeneration. Stem Cell Dev 2011; 20 (3): 451-63.
74. Evangelista M, Soncini M, Parolini O. Placenta-derived stem cells: new hope for cell therapy? Cytotechnology 2008; 58 (1): 33-42.
75. Cargnoni A, Di Marcello M, Campagnol M, Nassuato C, Albertini A, Parolini O. Amniotic membrane patching promotes ischemic rat heart repair. Cell Transplant 2009; 18 (10): 1147-59.
76. Parolini O, Caruso M. Review: preclinical studies on placentaderived cells and amniotic membrane: an update. Placenta 2011; 25 (Suppl 2): S186-95.
77. Rossi D, Pianta S, Magatti M, Sedlmayr P, Parolini O. Characterization of th conditionated medium from amniotic membrane cells. Prostaglandins as a key effectors of its immunomodulatory activity. PLoS One 2012; 7 (10): e46956.
78. Karahuseyinoglu S, Cinar O, Kilic E, et al. Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cell 2007; 25 (2): 319-31.
79. Hoyes AD. Ultrastructure of the epithelium of the human umbilical cord. J Anat 1969; 105 (Pt1): 149-62.
80. Nanaev AK, Kohen G, Milovanov AP, Domogatsky SP, Kaufmann P. Stromal differentiation and architecture of the human umbilical cord. Placenta 1997; 18 (1): 53-64.
81. Can A, Karahuseyinoglu S. Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells 2007; 25 (11): 2886-95.
82. Ryynänen J, Tan EM, Hoffren J, Woodley DT, Sollberg S. Type VII collagen gene expression in human umbilical tissue and cells. Lab Invest 1993; 69 (3): 300-4.
83. Sobolewski K, Małkowski A, Bańkowski E, Jaworski S. Wharton's jelly as a reservoir of peptide growth factors. Placenta 2005; 26 (10): 747-52.
84. Takechi K, Kuwabara Y, Mizuno M. Ultrastructural and immunohistochemical studies of Wharton's jelly umbilical cord cells. Placenta 1993; 14 (2): 235-45.
85. Majno G, Gabbiani G, Hirschel BJ, Ryan GB, Statkov PR. Contraction of granulation tissue in vitro: similarity to smooth muscle. Science (Washington) 1971; 173 (3996): 548-50.
86. Gabbiani G, Hirschel BJ, Ryan GB, Statkov PR, Majno G. Granulation tissue as a contractile organ. J Exp Med 1972; 135 (4): 719-34.
87. Kobayashi K, Kubota T, Aso T. Study on myofibroblast differentiation in the stromal cells of Wharton's jelly: expression and localization of alpha-smooth muscle actin. Early hum Dev 1998; 51 (3): 223-33.
88. Qiao C, Xu W, Zhu W, et al. Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int 2008; 32 (1): 8-15.
89. Conconi MT, Di Liddo R, Tommasini M, Calore C, Parnigotto PP. Phenotype and differentiation potential of stromal populations obtained from various zones of human umbilical cord: an overview. Open Tissue Eng Regen Med J 2011; 4 (1): 6-20.
90. Jeschke MG, Gauglitz GG, Phan TT, Herndon DN, Kita K. Umbilical cord lining membrane and Wharton's jelly-derived mesenchymal stem cells: the similarities and differences. Open Tissue Eng Regen Med J 2011; 4 (1): 21-7.
91. De Kock J, Najar M, Bolleyn J, et al. Mesoderm-derived stem cells: the link between the transcriptome and their differentiation potential. Stem Cells Dev 2012; 21(18): 3309-33.
92. La Rocca G, Anzalone R, Corrao S, et al. Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochem Cell Biol 2009; 131 (2): 267-82.
93. Prasanna SJ, Jahnavi VS. Wharton's jelly mesenchymal stem cells as off-the-shelf cellular therapeutics: a closer look into their regenerative and immunomodulatory properties. Open Tissue Eng Regen Med J 2011; 4 (1): 28-38.
94. Anzalone R, Lo Iacono M, Corrao S, et al. New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Stem Cell Dev 2010; 19 (4): 423-38.
95. Anzalone R, Lo Iacono M, Loria T, et al. Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev 2011; 7 (2): 342-63.
96. Anzalone R, Farina F, Zummo G, La Rocca G. Recent patents and advances on isolation and cellular therapy applications of mesenchymal stem cells from human umbilical cord Wharton's jelly. Recent Pat Regen Med 2011; 1: 216-27.
97. Lo Iacono M, Anzalone R, Corrao S, et al. Perinatal and Wharton's jelly-derived mesenchymal stem cells in cartilage regenerative medicine and tissue engineering strategies. Open Tissue Eng Regen Med J 2011; 4 (1): 72-81.
98. Anzalone R, Lo Iacono M, Corrao S, et al. Human Wharton's jellyderived mesenchymal stem cells express several immunomodulatory molecules both in their naïve state and hapatocyte-like differentiated progeny: prospects for their use in liver diseases. Placenta 2011; 32 (Suppl 4): S335.
99. Najar M, Raicevic G, Boufker HI, et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's jelly and bone marrow source. Cell Immunol 2010; 264 (2): 171-9.
100. Dayan V, Yannarelli G, Billia F, et al. Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction. Basic Res Cardiol 2011; 106 (6): 1299-310.
101. Corrao S, Campanella C, Anzalone R, et al. Human Hsp10 and Early Pregnancy Factor (EPF) and their relationship and involvement in cancer and immunity: current knowledge and perspectives. Life Sci 2010; 86 (5-6): 145-52.
102. La Rocca G, Anzalone R, Farina F. The expression of CD68 in human umbilical cord mesenchymal stem cells: new evidences of presence in non-myeloid cell types. Scand J Immunol 2009; 70 (2): 161-2.
103. Zhou C, Yang B, Tian Y, et al. Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes. Cell Immunol 2011; 272 (1): 33-8.
104. Kadner A, Zund G, Maurus C, et al. Human umbilical cord cells for cardiovascular tissue engineering: a comparative study. Eur J Cardiothorac Surg 2004; 25 (4): 635-41.
105. Turillazzi E, La Rocca G, Anzalone R, et al. Heterozygous nonsense SCN5A mutation W822X explains a simultaneous sudden infant death syndrome. Virchows Arch 2008; 453 (2): 209-16.
106. Turillazzi E, Pomara C, La Rocca G, et al. Immunohistochemical marker for Na+ CP type Valpha (C-20) and heterozygous nonsense SCN5A mutation W822X in a sudden cardiac death induced by mild anaphylactic reaction. Appl Immunohistochem Mol Morphol 2009; 17 (4): 357-62.
107. Breymann C, Schmidt D, Hoerstrup SP. Umbilical cord cells as a source of cardiovascular tissue engineering. Stem Cell Rev 2006; 2 (2): 87-92.
108. Costa Pereira W, Khushnooma I, Madkaikar M, Ghosh K. Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation. J Tissue Eng Reg Med 2008; 2: 394-9.
109. Hollweck T, Hartmann I, Eblenkamp M, et al. Cardiac Differentiation of Human Whartons jelly stem cells-Experimental comparison of protocols. Open Tissue Eng Regen Med J 2011; 4: 95-102.
110. La Rocca G. Connecting the dots: the promises of Wharton's jelly mesenchymal stem cells for tissue repair and regeneration. Open Tissue Eng Regen Med J 2011; 4: 3-5.